Company intelligence / Profile preview

General Therapeutics, Inc.

New York, New York, United Statesgeneraltherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company is conducting an Early Phase 1 clinical trial to evaluate the safety and efficacy of intraarticular injection of Cell-free Stem cell-derived Extract Formulation for treatment of knee osteoarthritis symptoms. The trial started on January 1, 2023, and is currently listed as "Not yet recruiting" as of the last update on January 23, 2025[1].

Therapeutic areas: Rheumatology
Modalities: Stem cell therapy
Industry: Biotech

Drug pipeline

1 asset

GTX LNP-pDNA

Preclinical

Beyond the preview

Go deeper on General Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on General Therapeutics, Inc..

Explore the full profile